4//SEC Filing
Hollander David 4
Accession 0001479290-24-000130
CIK 0001479290other
Filed
Nov 18, 7:00 PM ET
Accepted
Nov 19, 4:31 PM ET
Size
5.6 KB
Accession
0001479290-24-000130
Insider Transaction Report
Form 4
Hollander David
CMO & Global Therapeutics Lead
Transactions
- Sale
Common Stock
2024-11-18$4.17/sh−3,908$16,296→ 104,945 total
Footnotes (2)
- [F1]Represents the number of shares required to be sold by the Reporting Person, to cover tax withholding obligations in connection with the vesting of restricted stock units granted on October 17, 2022 which vest in equal installments over a four year period. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- [F2]The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Documents
Issuer
Revance Therapeutics, Inc.
CIK 0001479290
Entity typeother
Related Parties
1- filerCIK 0001793796
Filing Metadata
- Form type
- 4
- Filed
- Nov 18, 7:00 PM ET
- Accepted
- Nov 19, 4:31 PM ET
- Size
- 5.6 KB